This page uses content from Wikipedia and is licensed under CC BY-SA.
Asimadoline ( EMD-61753) is an experimental drug which acts as a peripherally selective κ-opioid receptor (KOR) agonist.  Because of its low penetration across the  blood–brain barrier, asimadoline lacks the psychotomimetic effects of centrally acting KOR agonists, and consequently was thought to have potential for medical use. It has been studied as a possible treatment for irritable bowel syndrome, with reasonable efficacy seen in clinical trials,  but it has never been approved or marketed.
Barber A, Gottschlich R; Gottschlich (October 1997). "Novel developments with selective, non-peptidic kappa-opioid receptor agonists". Expert Opinion on Investigational Drugs. 6 (10): 1351–68. doi: 10.1517/135437220.127.116.111. PMID 15989506.
Camilleri M (September 2008). "Novel pharmacology: asimadoline, a kappa-opioid agonist, and visceral sensation". Neurogastroenterology & Motility. 20 (9): 971–9. doi: 10.1111/j.1365-2982.2008.01183.x. PMC . 2698012 PMID 18715494.
Delvaux M, Beck A, Jacob J, Bouzamondo H, Weber FT, Frexinos J (July 2004). "Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome". Alimentary Pharmacology & Therapeutics. 20 (2): 237–46. doi: 10.1111/j.1365-2036.2004.01922.x. PMID 15233705.
Szarka LA, Camilleri M, Burton D, Fox JC, McKinzie S, Stanislav T, Simonson J, Sullivan N, Zinsmeister AR (November 2007). "Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome". Clinical Gastroenterology and Hepatology. 5 (11): 1268–75. doi: 10.1016/j.cgh.2007.07.011. PMC . 2128734 PMID 17900994.